Lazaridis, K. N. & Larusso, N. F. The cholangiopathies. Mayo Clin. Proc. 90, 791–800 (2015).
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D. & Adams, D. H. Primary sclerosing cholangitis. Lancet 382, 1587–1599 (2013).
Hirschfield, G. M. & Gershwin, M. E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. Mech. Dis. 8, 303–330 (2013).
Yoshida, K. et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor β receptor type II mice. Hepatology 50, 1494–1500 (2009).
Maroni, L. et al. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice. Hepatology 66, 542–554 (2017).
Jiang, X. & Karlsen, T. H. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat. Rev. Gastroenterol. Hepatol. 14, 279–295 (2017).
Trivedi, P. J. & Adams, D. H. Mucosal immunity in liver autoimmunity: a comprehensive review. J. Autoimmun. 46, 97–111 (2013).
Kamihira, T. et al. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. Hepatology 41, 151–159 (2005).
Barbatis, C. et al. Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody. Gut 22, 985–991 (1981).
Ballardini, G. et al. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 324, 1009–1013 (1984).
Chapman, R. W., Kelly, P. M., Heryet, A., Jewell, D. P. & Fleming, K. A. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 29, 422–427 (1988).
Feng, J., Li, M., Gu, W., Tang, H. & Yu, S. The aberrant expression of HLA-DR in intrahepatic bile ducts in patients with biliary atresia: an immunohistochemistry and immune electron microscopy study. J. Pediatr. Surg. 39, 1658–1662 (2004).
Leon, M. P. et al. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology 24, 561–567 (1996).
Kamihira, T. et al. Distinct costimulation dependent and independent autoreactive T-cell clones in primary biliary cirrhosis. Gastroenterology 125, 1379–1387 (2003).
Barnes, B. H. et al. Cholangiocytes as immune modulators in rotavirus-induced murine biliary atresia. Liver Int. 29, 1253–1261 (2009).
Schrumpf, E. et al. The biliary epithelium presents antigens to and activates natural killer T cells. Hepatology 62, 1249–1259 (2015).
Jeffery, H. C. et al. Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J. Hepatol. 64, 1118–1127 (2016).
Olsson, R. et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J. Hepatol. 28, 426–432 (1998).
Hiramatsu, K. et al. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J. Hepatol. 33, 9–18 (2000).
Arrese, M. & Trauner, M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9, 558–564 (2003).
Brennan, P. J., Brigl, M. & Brenner, M. B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13, 101–117 (2013).
Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 278, 1626–1629 (1997).
Santodomingo-Garzon, T. & Swain, M. G. Role of NKT cells in autoimmune liver disease. Autoimmun. Rev. 10, 1–8 (2011).
Eberl, G. et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162, 6410–6419 (1999).
Matsuda, J. L. et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192, 741–754 (2000).
Brossay, L. et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188, 1521–1528 (1998).
Exley, M. et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 100, 37–47 (2000).
Canchis, P. W. et al. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 80, 561–565 (1993).
Tupin, E., Kinjo, Y. & Kronenberg, M. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5, 405–417 (2007).
van der Vliet, H.J. et al. Circulating Vα24+Vβ11+NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100, 144–148 (2001).
Akbari, O. et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9, 582–588 (2003).
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252 (2012).
Kaneko, Y. et al. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191, 105–114 (2000).
Wondimu, Z., Santodomingo-Garzon, T., Le, T. & Swain, M. G. Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am. J. Pathol. 177, 2334–2346 (2010).
Kita, H. et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123, 1031–1043 (2002).
Durante-Mangoni, E. et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 173, 2159–2166 (2004).
Kakimi, K., Guidotti, L. G., Koezuka, Y., & Chisari, F. V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192, 921–930 (2000).
Zeissig, S. et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 18, 1060–1068 (2012).
Mattner, J. et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3, 304–315 (2008).
Boirivant, M, Fuss, I. J, Chu, A. & Strober, W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188, 1929–1939 (1998).
Nieuwenhuis, E. E. S. et al. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp. Dermatol. 14, 250–258 (2005).
Heller, F., Fuss, I. J., Nieuwenhuis, E. E., Blumberg, R. S. & Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629–638 (2002).
Osman, Y. et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur. J. Immunol. 30, 1919–1928 (2000).
Barral, D. C. & Brenner, M. B. CD1 antigen presentation: how it works. Nat. Rev. Immunol. 7, 929–941 (2007).
Im, J. S. et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30, 888–898 (2009).
Wal, Yvande et al. Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells. Gastroenterology 124, 1420–1431 (2003).
Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E. & Brenner, M. B. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4, 1230–1237 (2003).
Olszak, T. et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509, 497–502 (2014).
Sonoda, K.-H., Exley, M., Snapper, S., Balk, S. P. & Stein-Streilein, J. Cd1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190, 1215–1225 (1999).
Berntsen, N. L. et al. Establishment of a surgical bile duct injection technique giving direct access to the bile ducts for studies of the murine biliary tree. Am. J. Physiol. Liver Physiol. 314, G349–G359 (2018).